Company profile
THC Farmaceuticals, Inc.
OTC: CBDG · Healthcare · Biotechnology
#1119 of 1,422 Healthcare companies by revenue31st-percentile growth
EA Score
——FH —DQ 23GM —SS 30
v0.1 · 25/100 weight · pillars only
↑ growth stability, Altman-Z · ↓ workforce scale, balance-sheet leverage
Methodology →Revenue TTM
$15.0k
Rev growth YoY (TTM)
+28.1%
Net income (FY)
-$30.7k
Employees
2
as of 2026-08-27
Market cap
$505.9k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$19.0k$19.0k2014
Net income-$30.7k-$30.7k2014
Operating income-$24.0k-$24.0k2014
Total assets$48.1k$48.1k2014
Liabilities$96.2k$96.2k2014
Equity-$48.0k-$48.0k2014
Revenue trend
FY2011 – FY2014 · USD
FY11
FY11
FY12
FY13
FY14
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is THC Farmaceuticals, Inc.’s revenue?
THC Farmaceuticals, Inc. booked $19.0k in FY2014 revenue, contracting 12% year over year — slower than 69% of Healthcare companies we track, at a -161.3% net margin.
Peers · Healthcare
Jupiter Neurosciences, Inc.18DSkinvisible, Inc.29DSouth American Gold Corp.——Sector 10, Inc.——Nanobac Pharmaceuticals, Incorporated——REMSleep Holdings, Inc.19DNeighbors
Maricopa →Key facts
CEOMark D. Grossman
SectorHealthcare
IndustryBiotechnology
HeadquartersScottsdale, AZ
ExchangeOTC: CBDG
Employees2
IPO date2014-01-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.